Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.
The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.
A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
Most of the time, uterine cold is caused by too much cold energy in the body.
The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours
An obvious feature of autumn that is different from summer is that the temperature drops, the weather is unpredictable, and the temperature difference between morning and night is large, which has become one of the main causes of female biological clock disorder, endocrine disorder and bacterial infection in autumn. In addition, the resistance of the human body decreases relatively in autumn, which is also a time of high recurrence for patients with gynecological diseases.
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.
According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!
Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.
Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.
